BLRX News and Press, BioLineRx Ltd. From 03/06/24

2024-03-06 08:40:19 ET Vancouver, Kelowna and Delta, British Columbia – March 6, 2024 – Investorideas.com , a global investor news source covering biotech and pharma stocks issues a sector snapshot on developments for pancreatic cancer treatments, featuring Oncolytics Bi...

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production PR Newswire - New patent, when issued, will be valid until December 2041 - - Add...

BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) PR Newswire - Conducted in Collaboration with Columbia University , the CheMo4METPANC Phase 2 trial is the first large, ...

2024-02-25 14:12:12 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In almost every situation, investors should stay away from penny stocks . They’re extremely speculative and they tend to facilitate delusions of grandeur. To be sure, there’s ...

BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR® PR Newswire Results include pharmaco...

2023-12-29 16:26:31 ET More on biolinerx BioLineRx: Still A Buy, With Some Questions biolinerx GAAP EPS of -$0.01 BioLineRx announces closing of exclusive license agreement with GloriaBio For further details see: BioLineRx files for a $250M mixed securiti...

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease PR Newswire - Proof-of-concept study is initial step toward goal of identifying more efficient...

2023-12-04 18:42:54 ET Summary BioLineRx gains approval for a blood cancer drug that aids in stem cell transplantation. Motixafortide, the flagship drug, shows promising results in mobilizing blood stem cells and in combination with other treatments for pancreatic cancer. Fina...

2023-12-02 23:25:30 ET Summary BioLineRx is a biopharmaceutical company specializing in cancer and rare disease therapies. The company's main product, Aphexda, was FDA-approved for stem cell mobilization in multiple myeloma patients. BioLineRx's low cash reserves and need for ...

2023-11-20 13:54:04 ET BioLineRx Ltd. (BLRX) Q3 2023 Earnings Conference Call November 20, 2023 10:00 PM ET Company Participants John Lacey - Head of IR & Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO ...